WEBINAR ON DEMAND
Duration: 1 hour

If you were born during the Spanish Flu, your risk of Parkinson’s was 2 to 3 times higher than if you were born before 1888 or after 1924. As the COVID-19 generation, are we at a similar risk today? 

Recently, researchers tackled that question as they replicated a midcentury study that observed the connections between Parkinson’s and the H1N1 Spanish flu—except this time, studying SARS-CoV-2 instead. Join study author Pete Schmidt, PhD (Rho) and Mark Stacy, MD (MUSC Health) as they discuss the new study, including what biopharma sponsors should know about its implications and opportunities for future movement disorder research. You’ll learn:

• Why researchers explored the connections between COVID-19 and Parkinson’s similar to what’s been done with previous outbreaks including H1N1, HIV, and polio
• Opportunities for biopharma sponsors ahead of an expected future wave of Parkinson’s patients
• The COVID-19 pandemic’s implications for drug development and management of movement disorders

SPEAKERS

Peter Schmidt, Ph.D
Chief Scientific Officer
Rho

Mark Stacy, MD
Neurologist
Medical University of South Carolina